Javelin Pharmaceuticals complies with Amex rules

Javelin Pharmaceuticals Inc., a Cambridge company focused on pain-management treatments, said today that it has regained compliance with American Stock Exchange rules regarding director independence.

The company said it reported in a Securities and Exchange filing earlier this month that it had determined that Martin Driscoll, a company director, no longer qualified as independent.

But on Feb. 18, Javelin said its board elected Peter D. Kiernan III as a director and qualified him as independent under the Amex Rules.

The company further added that its corporate governance and nominating committee met Feb. 24 and reviewed the independence requirements for directors; the committee determined that of the board's eight directors, five qualify as independent under Amex rules.
(By Chris Reidy, Globe staff)